长效针剂与口服抗精神病药在老年精神分裂症中的比较:疾病复发、全因死亡与不良事件
该研究基于香港医院管理局全港电子健康记录,对1993至2023年诊断为精神分裂症、2004至2023年使用长效针剂或口服抗精神病药的65岁及以上患者进行自身对照分析。
要点
- 锥体外系症状风险升高仅见于第一代长效针剂,第二代未见显著增加。
核心结论
- 在老年精神分裂症患者中,长效针剂与口服抗精神病药相比,与更低的疾病复发和全因死亡风险相关,且未增加心血管住院、急性肝损伤和急性肾损伤风险。
- 锥体外系症状风险升高仅与第一代长效针剂相关,第二代长效针剂未见显著增加。
- 作者认为长效针剂尤其是第二代药物可更广泛考虑用于该人群的长期治疗,尤其在疾病早期。
研究设计与样本
- 基于香港医院管理局临床数据库分析及报告系统的全港电子健康记录,进行基于人群的自身对照分析。
- 纳入1993年1月1日至2023年12月31日诊断为精神分裂症(ICD-9-CM 295)且2004年1月1日至2023年12月31日期间年龄≥65岁并处方长效针剂或口服抗精神病药的个体,排除人口学信息不完整者。
- 采用自身对照病例系列研究设计,用泊松回归比较长效针剂与口服药治疗期间疾病复发和不良事件风险;全因死亡采用个体分层Cox回归。
- 调整时变混杂因素包括年龄、季节、抗精神病药类别、COVID-19严格指数以及合并使用抗抑郁药、苯二氮䓬类或Z类药物、心境稳定剂和抗帕金森病药物。
主要发现
- 心血管住院、急性肝损伤和急性肾损伤风险在长效针剂与口服药之间无统计学显著差异。
关键数值与推荐
- 疾病复发定义为因精神分裂症住院。
- 不良事件包括心血管住院、锥体外系症状、急性肝损伤和急性肾损伤,通过ICD-9-CM编码或实验室检查识别。
- 主要比较指标为发生率比(IRR)和风险比(HR),并报告95%置信区间和p值。
临床怎么用
- 对于老年精神分裂症患者,长效针剂尤其是第二代药物可考虑用于长期治疗以降低复发和死亡风险,尤其在疾病早期。
- 使用第一代长效针剂时需监测锥体外系症状。
- 长效针剂未增加心血管住院、急性肝损伤和急性肾损伤风险,但需结合个体情况评估。
局限性
- 数据中种族信息不可用。
- 研究为观察性设计,可能存在残余混杂。
- 有精神分裂症亲身经历者未参与研究设计或实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older individuals (aged ≥65 years) with schizophrenia are at increased risk of treatment non-adherence due to cognitive decline and complex polypharmacy. Use of long-acting injectable (LAI) antipsychotics in this population has not been systematically investigated. We aimed to compare risk of disease relapse, all-cause mortality, and adverse events associated with LAI versus oral antipsychotics among older people with schizophrenia. METHODS: In this population-based within-subject analysis, we used territory-wide electronic health records from the Clinical Database Analysis and Reporting System of the Hong Kong Hospital Authority. Individuals diagnosed with schizophrenia (ICD-9-CM code 295) in inpatient, outpatient, or emergency department settings between Jan 1, 1993, and Dec 31, 2023, were identified, and people aged 65 years and older who were prescribed LAI or oral antipsychotics between Jan 1, 2004, and Dec 31, 2023, were considered for inclusion. Individuals with incomplete demographic information were excluded. The primary outcome was disease relapse, defined as hospital admission for schizophrenia. The secondary outcomes comprised all-cause mortality and adverse events, including cardiovascular hospital admission, extrapyramidal symptoms, acute liver injury, and acute kidney injury, which were identified using ICD-9-CM codes or laboratory tests. A self-controlled case series study using Poisson regression was conducted to compare the risk of disease relapse and adverse events between the treatment periods of LAI and oral antipsychotics. An individual-stratified Cox regression was performed for all-cause mortality. Time-varying confounders, including age, season, class of antipsychotics, COVID-19 stringency index, and concomitant treatment with antidepressants, benzodiazepines or Z-drugs, mood stabilisers, and antiparkinsonian drugs, were adjusted for. People with lived experience of schizophrenia were not involved in the design or conduct of the study. FINDINGS: Of 24 985 older individuals with schizophrenia, 4696 (18·8%) were prescribed LAI or oral antipsychotics. 10 655 (42·6%) of 24 985 individuals were male and 14 330 (57·4%) were female. Data on ethnicity were not available. Compared with oral antipsychotics, LAI antipsychotics were associated with statistically significantly lower risk of hospital admission for schizophrenia (incidence rate ratio [IRR] 0·71 [95% CI 0·64-0·78], p<0·0001) and all-cause mortality (hazard ratio [HR] 0·23 [95% CI 0·12-0·44], p<0·0001). No statistically significant difference was found in cardiovascular hospital admissions, acute liver injury, and acute kidney injury. LAI antipsychotics were associated with increased risk of extrapyramidal symptoms (IRR 2·17 [1·24-3·80], p=0·0068), but only with first-generation (2·86 [1·41-5·84], p=0·0038) not second-generation LAI antipsychotics. INTERPRETATION: In older individuals with schizophrenia, LAI antipsychotics were associated with lower risk of disease relapse and mortality, without increased risk of adverse events, than oral antipsychotics, except for elevated risk of extrapyramidal symptoms specifically related to first-generation LAI antipsychotics. Overall, LAI antipsychotics, especially second-generation medications, could be more broadly considered for long-term use among this population, particularly at an early stage of disease. FUNDING: National Natural Science Foundation of China.
引用
- Wei Y, Yan VKC, Castle DJ, et al. Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis. Lancet Psychiatry. 2025. PMID: 41043453. doi:10.1016/S2215-0366(25)00268-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。